Background: The goal of this pilot study was to design an external quality assessment (EQA) scheme for German cystic fibrosis (CF) clinical microbiology laboratories. Therefore, a multicentre-study of 18 German CF laboratories was performed to evaluate their proficiency in analysing CF respiratory secretions.
Introduction
Cystic fibrosis (CF) is the most common hereditary disease in the Caucasian population and results from mutations in the CF transmembrane conductance regulator (CFTR) gene. The CFTR defect leads to an imbalance in the epithelial electrolyte transport and multiple organ dysfunctions. In the CF lung, copious amounts of viscous respiratory secretions and impaired airway clearance cause recurrent bacterial infections with intense inflammation, airway obstruction, progressive lung tissue destruction and ultimately respiratory failure [1, 2] .
CF lung infection typically begins with the acquisition of Staphylococcus aureus and
Haemophilus influenzae, followed by chronic Pseudomonas aeruginosa pneumonia, that remains the major cause of morbidity and mortality among CF patients [3] [4] . In addition,
Burkholderia cepacia complex, Stenotrophomonas maltophilia, Achromobacter xylosoxidans,
non-tuberculosis mycobacteria and emerging pathogens like Pandoraea spp. and Inquilinus limosus further aggravate pulmonary infection in CF patients [5] [6] [7] [8] [9] .
As a consequence of this progressive microbiological history periodical microbiological examinations of CF respiratory secretions remain cornerstones in the clinical management of CF lung disease. [10] [11] [12] .
Thus, accurate microbiological diagnostic employed on CF respiratory secretions is critical to ensure appropriate anti-microbial treatment and the implementation of reliable hygienic measures like segregation of patients with a respiratory tract culture that is positive for P. aeruginosa or Burkholderia cepacia complex.
During chronic stages of CF pneumonia microbiological examinations are complicated by the fact that respiratory samples obtained from CF patients often contain a mixture of different species and/or high quantities of diverse morphotypes and resistotypes, such as mucoid and non-mucoid P. aeruginosa, biochemical inactive, small colony, hypermutable and multidrug resistant (MDR) variants of pathogens that persisted for years [3, 13, 14] .Cultures performed on CF specimens commonly involve the use of many medium types, in particular selective media that facilitate the recovery of potential pathogens such as S. aureus, P. aeruginosa and B. cepacia complex from the complex microflora of CF airway secretions [15] [16] [17] [18] . Therefore, the microbiological diagnosis of CF respiratory tract infections is labor-intensive and implies a wide experience in the field of CF microbiology.
About 8000 patients suffering from CF live in the Federal Republic of Germany and most of them are followed at about 120 different CF centres. In agreement, respiratory secretions of CF patients are analysed in several microbiological laboratories all over Germany and on request by two consiliary laboratories on CF microbiology appointed by the Robert Koch Institute (in Munich: Consiliary Laboratory South, CLSth and in Hanover: Consiliary Laboratory North, CLNth).
To assess and continuously improve the quality of the microbiological laboratory performance in Germany, national external quality assessment (EQA) schemes are generally conducted for all kinds of routine microbiological procedures based on quality standards in microbiology-infectiologic diagnostics, denoted as MiQ and issued by the German Society for Hygiene and Microbiology. EQA trials are organized and performed by the INSTAND organization (Institute for Standardization and Documentation in Medical Laboratories) on behalf of the Board of the Federal Medical Council. However, during this study neither specific recommendations for clinical microbiology protocols, as available from American authorities, nor EQA schemes for CF respiratory tract samples existed in Germany [19, 21] .
In summary, the reliable microbiological diagnosis of CF lung infections imposes a particular challenge for clinical microbiology laboratories due to (i) the unique spectrum of typical CF pathogens and a variety of rarely occurring unusual non-fermentative bacteria (ii) the broad phenotypic diversity of CF isolates descending from one initial infecting clone and (iii) the increasing selection of MDR variants. The aim of this study was to design an EQA scheme for German microbiological laboratories regularly processing CF respiratory tract specimens.
Therefore, a multilaboratory trial was organised by preparing simulated CF specimens that were sent by mail to 18 CF microbiological laboratories. The proficiency of participants was assessed regarding isolation, identification and antimicrobial susceptibility testing (AST) of classical CF pathogens. Moreover they were asked to complete a questionnaire about applied "in-house" laboratory protocols.
In conclusion, the results of this study revealed important reporting errors in terms of CF test specimens and relevant differences in routine laboratory procedures and argue for the implementation of a continuous German EQA programme based on harmonized methodologies to improve the microbiological diagnosis of respiratory samples from CF patients.
Materials and methods

Bacterial strains and test specimens
Two identical freeze-dried simulated samples containing 4 bacterial strains of CF origin were distributed to each participating laboratory (for each strain cell densities of 1.0 x 10 8 /ml were intended 
Report forms and questionnaires
A report form was provided for each of the four CF test strains included in the samples.
Herein, 12 antimicrobial agents were listed and the participants were asked to report these agents and any other antibiotic agent they routinely test by using their standard AST procedures. Due to the estimated broad spectrum of AST methodologies, the microbiological laboratories were asked to score their AST results primarily as susceptible, intermediate and resistant but to append MIC values if available. The supplied questionnaire covered details of cultivation (e.g. media, cultivation temperature and time), species identification and AST procedures.
Results
Clinical microbiology laboratory results and protocols were provided by 17 of the 18 participating CF laboratories. Cultivation media, methods for species identification and AST of the laboratories and microbiological results of simulated CF specimens are summarized in Table 1 -4, respectively. 
Laboratory results of bacterial cultivation and species identification
Laboratory cultivation protocols
All 17 laboratories prepared cultivation media by streaking reconstituted freeze-dried samples using loop inoculation, while two laboratories in addition plated serial dilutions of the reconstituted samples and reported on CFU/ml of individual pathogens. and 30°C, respectively. Six laboratories used prolonged incubation for Burkholderia cepacia complex selective media and/or fungal selective media up to seven days at RT.
All four laboratories successfully cultivating P. aeruginosa 2 used loop inoculation for preparation of cultivation media and 48 h incubation, two at 36°C and one of them at 35°C, while one laboratory did not report on the incubation temperature. Surprisingly, the two laboratories using serial dilutions, suggesting improved recovery of different species and morphotypes from CF samples, and the single laboratory using Meropenem agar for selection of MDR phenotypes also missed P. aeruginosa 2.
Antimicrobial susceptibility testing
AST methods applied by participating laboratories and reported category results (S/I/R) are shown in Table 3 [26] . Likewise, overlooking of P. aeruginosa 2 could result in the selection of an in-effective antibiotic treatment.
The evaluation of the questionnaires revealed a broad heterogeneity between microbiological protocols regarding cultivation and AST procedures. Cultivation procedures implemented for non-CF specimens may fail to detect fastidious species found in CF specimens like Burkholderia cepacia complex, slow growing mucoid P. aeruginosa or small colony variants (SCV) that can easily be overgrown by other micro-organisms. Failure in the recovery of these CF pathogens may negatively influence clinical treatment, as probably important etiologic pathogens or more resistant components of the infection will be missed. Further, the omission or the delayed separation of infected patients may lead to an increased risk of patient-to-patient transmission.
For the primary processing of CF respiratory specimens the use of selective media and prolonged incubation periods are essential. For the optimal recovery of gram-negative bacteria, mainly P. aeruginosa, selective media such as Pseudomonas isolation, cetrimide, MacConkey or acetamide agar are required. To improve the recovery of H. influenzae, chocolate agar supplemented with vancomycin and/or bacitracin and clindamycin is recommended [15] . Due to the high transmissibility of some Burkholderia cepacia complex species and their association with a poor prognosis, the use of isolation media with enhanced recovery rate for this organism are striktly recommended (e.g. MAST selective agar, Burkholderia cepacia selective agar, Pseudomonas cepacia agar, oxidation-fermentation polymyxin bacitracin lactose agar, Stewart's composite arginine medium) [16] [17] [18] [19] . To ensure the reliable recovery of S. aureus, mannitol salt agar or other media have been used (e.g.
Columbia colistin-nalidixic acid agar, lipase-salt-mannitol agar). For the recovery of S. aureus
SCVs chromogenic agar media were shown to be reliable (e.g. S. aureus ID agar, CHROMagar Staph aureus) [27] . Detection of MDR variants is facilitated by agar media supplemented with antibiotics, like meropenem, tobramycin or colistin [28] [29] [30] [31] .
As a consequence, in CF selective media have been advocated by american authorities for the optimum recovery of H. influenzae, S. aureus, P. aeruginosa and Burkholderia cepacia complex [19] . Surprisingly, only eight of 17 laboratories used selective media for S. aureus and 12 of 17 laboratories for Burkholderia cepacia complex. Although the high bacterial load of S. aureus and B. multivorans most likely enabled all laboratories to detect both strains without usage of specific selective media, these pathogens could be missed when lower CFU are present and/or more rapidly growing species (e.g. P. aeruginosa) obscure their detection [32] . Likewise, the overlooking of P. aeruginosa 2 appear to be the result of the more prominent colony size and/or slighly higher cell count of P. aeruginosa 1, S. aureus and B.
multivorans. While almost all participating laboratories prepared bacterial cultures only by loop-inoculation of undiluted samples, quantitative cultures performed by CLSth and CLNth demonstrated that P. aeruginosa 2 was present in easily detectable amounts. This underlines the need of adequate sample homogenisation and whole plate inoculation of serial dilutions to efficiently separate different CF pathogens and phenotypic variants from the more challenging viscous CF airway secretions that in contrast to the homogeneous freeze-dried sample contain heterogeneously distributed bacteria in biofilm-like microcolonies.
For species identification the majority of laboratories used biochemical methods while three laboratories confirmed B. cepacia complex identification by 16S rDNA sequencing. Several studies have shown that conventional biochemical tests can misidentify B. cepacia complex species, biochemical inactive and newly emerging CF pathogens [6, 33] . Thus, laboratories processing CF specimens need access to molecular identification tools and/or in equivocal cases the possibility to send specimens and/or isolates to national or international referral laboratories on CF microbiology [34] . Services regarding the genomic species identification of B. cepacia complex isolates are available by the European Burkholderia cepacia complex
Referral Laboratory and Repository (information via http://go.to/cepacia).
Moreover, accurate AST in particular of highly resistant CF isolates plays a critical role in the diagnostic microbiology [35] . The evaluation of the questionnaires revealed that most laboratories used either automated commercial systems (13 of 17 laboratories) and/or the disc diffusion method (11 of 17 laboratories), whereas either CLSI or DIN guidelines were used.
Most categorical errors occurred when automated systems were applied followed by the agar diffusion test. The overall strain-specific error rates for AST results were found to be as In general, instead of the labor-intense agardilution method mainly the broth microdilution method and the agar-bond disk diffusion test have been considered to be appropriate for the AST of CF strains [36, 37] . Nevertheless, the disc diffusion testing of fastidious CF isolates, especially for mucoid P. aeruginosa, may be inaccurate [36] . The use of automated commercial systems (Vitek and MicroScan-WalkAway) for testing CF pathogens was shown to be inaccurate and thus has not been recommended by American authorities [38] . The wide use of automated systems among participants may account for a high number of reported AST errors. However, up-to-date studies evaluating newer generations of automated systems in the field of CF microbiology are not available. The Merlin Micronaut system was shown to be reliable for P. aeruginosa CF isolates [39] [40] . In 2005 revised CLSI guidelines have been released that for the first time include an approval of the disc diffusion for the testing of B.
cepacia complex and S. maltophilia when prolonged incubation times and adapted breakpoints are used. Nevertheless, the most suitable AST method of isolates obtained from CF patients is increasingly under debate. Beyond methodological discrepancies the poor correlation of in vitro data and the outcome of the patients is disappointing, irrespective of the testing of single antibiotics or antibiotic combinations [41] [42] [43] . This seems to be not surprisingly, since (i) the definition of resistance deduced from in vitro testing of bacteria and discrete clinical breakpoints is directed in particular towards the treatment of acute infections and does not equally fit to the situation of chronic infections (ii) in CF only a few possibly representative isolates were tested and (iii) rather all in vitro methods are inappropriate to mimic the complex environment of the CF lung comprising various sputum components, high bacterial densities, biofilm growth, anaerobiosis and the coexistence of different species or phenotypic variants. [44] .
Nevertheless, until adaequate AST protocols that provide a more rational basis for prescribing antibiotics for CF lung infection are missing, reliable conventional AST data should not be rejected since they may be still essential to guide antibiotic therapies during early CF disease and exacerbations and to unmask multiresistant isolates with respect to epidemiological and hygienic purposes [45] [46] .
In conclusion, this study highlighted that national EQA schemes are important to assess and improve the microbiological performance of CF respiratory tract specimens. As a part of this project, recommendations for German clinical microbiology laboratories processing CF respiratory secretions were recently published [21] . Probably yearly conducted EQA schemes are desirable to periodically evaluate the compliance of microbiological laboratories to guidelines that should be regularly updated e.g. with respect to changes in the epidemiology of CF lung infection. Table 4 Consiliary laboratories and participants antimicrobial susceptibility testing results a
